-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, MKVHoa4s+Ra+zvZSNzRQytWbVCPXYaEOMH4RijR5YbI452j0rTo2Z44OIJ3VIXG9 mBWGjDuHRkcSLmQJGhjL8Q== /in/edgar/work/0000950123-00-010841/0000950123-00-010841.txt : 20001121 0000950123-00-010841.hdr.sgml : 20001121 ACCESSION NUMBER: 0000950123-00-010841 CONFORMED SUBMISSION TYPE: SC TO-T/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20001120 GROUP MEMBERS: KONINKLIJKE PHILIPS ELECTRONICS NV GROUP MEMBERS: PHILIPS HOLDING USA INC GROUP MEMBERS: PHILIPS MEDICAL ACQUISITION CORP SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ADAC LABORATORIES CENTRAL INDEX KEY: 0000313798 STANDARD INDUSTRIAL CLASSIFICATION: [3844 ] IRS NUMBER: 941725806 STATE OF INCORPORATION: CA FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: SC TO-T/A SEC ACT: SEC FILE NUMBER: 005-32403 FILM NUMBER: 772778 BUSINESS ADDRESS: STREET 1: 540 ALDER DR CITY: MILPITAS STATE: CA ZIP: 95035 BUSINESS PHONE: 4083219100 MAIL ADDRESS: STREET 1: 540 ALDER DR CITY: MILPITAS STATE: CA ZIP: 95035 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: KONINKLIJKE PHILIPS ELECTRONICS NV CENTRAL INDEX KEY: 0000313216 STANDARD INDUSTRIAL CLASSIFICATION: [3600 ] STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC TO-T/A BUSINESS ADDRESS: STREET 1: REMBRANDT TOWER AMSTELPLEIN 1 STREET 2: 1096 HA AMSTERDAM CITY: THE NETHERLANDS MAIL ADDRESS: STREET 1: REMBRANDT TOWER AMSTELPLEIN 1 STREET 2: 1096 HA AMSTERDAM CITY: THE NETHERLANDS FORMER COMPANY: FORMER CONFORMED NAME: PHILIPS ELECTRONICS N V DATE OF NAME CHANGE: 19930727 SC TO-T/A 1 y42617a2scto-ta.txt AMENDMENT NO. 2 TO SCHEDULE TO 1 As filed with the Securities and Exchange Commission on November 17, 2000 OMB APPROVAL OMB Number: 3235-0515 Expires: January 31, 2002 Estimated average burden hours per response: 43.5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 Schedule TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) ADAC Laboratories (Name of Subject Company (Issuer)) Philips Medical Acquisition Corporation a Wholly Owned Subsidiary of Philips Holding USA Inc. a Wholly Owned Subsidiary of Koninklijke Philips Electronics N.V. (Names of Filing Persons) COMMON STOCK, NO PAR VALUE (Title of Class of Securities) 005313200 (CUSIP Number of Class of Securities) William E. Curran President Philips Holding USA Inc. 1251 Avenue of the Americas New York, New York 10020 (Name, address, and telephone numbers of person authorized to receive notices and communications on behalf of filing persons) with a copy to: Matthew G. Hurd, ESQ. Sullivan & Cromwell 125 Broad Street New York, New York 10004-2498 (212) 558-4000 2 - -------------------------------------------------------------------------------- CALCULATION OF FILING FEE Transaction valuation(1) Amount of filing fee $489,852,842 $97,971 - -------------------------------------------------------------------------------- (1) Based on the offer to purchase all of the outstanding shares of common stock of ADAC Laboratories, together with the associated rights to purchase Series A Junior Participating Preferred Stock, at a purchase price of $18.50 per share, 21,136,116 shares outstanding and outstanding options with respect to 5,342,416 shares, in each case as of November 12, 2000. [X] Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. Amount Previously Paid: $97,971 Form or Registration No.: 005-32403 Filing Party: Koninklijke Philips Electronics N.V. Date Filed: November 14, 2000 [ ] Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. Check the appropriate boxes below to designate any transactions to which the statement relates: [X] third-party tender offer subject to Rule 14d-1. [ ] issuer tender offer subject to Rule 13e-4. [ ] going-private transaction subject to Rule 13e-3. [ ] amendment to Schedule 13D under Rule 13d-2. Check the following box if the filing is a final amendment reporting the results of the tender offer:[ ] The information in the Offer to Purchase, including all schedules and annexes thereto, is hereby incorporated by reference in response to all the items of this Schedule TO, except as otherwise set forth below. Item 4. Terms of the Transaction. Item 4 of this Schedule TO is hereby amended and supplemented to include the following as the final paragraph of Section 13 of the Offer to Purchase entitled "Certain Conditions of the Offer": On November 17, 2000, ADAC Laboratories ("ADAC") advised Koninklijke Philips Electronics N.V. that the merger of a subsidiary of Cerner Corporation with and into ADAC Healthcare Information Systems, Inc. ("HCIS") became effective thereby making HCIS a subsidiary of Cerner Corporation and satisfying one of the conditions to the Offer. Item 11. Additional Information. Item 11 of this Schedule TO is hereby amended and supplemented to include the following as the final paragraph of Section 15 of the Offer to Purchase entitled "Certain Legal Matters": On November 15, 2000, ADAC advised Koninklijke Philips Electronics N.V. that three class action complaints were filed in the Superior Court of the State of California on November 13, 2000, in and for the County of Santa Clara, against ADAC and its current directors. The three class actions are Sidney Olmsted v. ADAC Laboratories, et al.; Joel Gerber v. ADAC Laboratories, et al; and Boris Rimensberger v.ADAC Laboratories, et al. The complaints allege that defendants breached their fiduciary duties to ADAC's shareholders in connection with the negotiation and execution of the Merger Agreement. Each complaint seeks declaratory and injunctive relief including enjoining the Merger, rescinding the Agreement and Plan of Merger and related documents, directing the individual defendants to obtain a transaction in the best interest of ADAC's shareholders until the process for the sale or auction of ADAC is completed, and costs and attorneys' fees. Copies of each complaint are attached hereto as Exhibits 99(a)(8), 99(a)(9) and 99(a)(10). The Company and the individual directors believe that the actions are without merit, and intend to defend them vigorously. The above summary is qualified in its entirety by reference to the Complaints, copies of which are attached as Exhibits 99(a)(8), 99(a)(9) and 99(a)(10) to this Schedule TO and incorporated herein by reference. Item 12. Exhibits. The following are attached as exhibits to this Schedule TO: 99(a)(8)(+) Complaint in Sidney Olmsted v. ADAC Laboratories, et al., No. CV793923, Superior Court of the State of California, County of Santa Clara. 99(a)(9)(+) Complaint in Gerber v. ADAC Laboratories, et al., No. CV793924, Superior Court of the State of California, County of Santa Clara. 99(a)(10)(+) Complaint in Boris Rimensberger v. ADAC Laboratories, et al. No. CV793928, Superior Court of the State of California, County of Santa Clara. (+) Filed as Exhibits 8, 9 and 10 to ADAC Laboratories' Amendment No. 2 to its Schedule 14D-9. 3 SIGNATURE After due inquiry and to the best of my knowledge and belief, we certify that the information set forth in this statement is true, complete and correct. PHILIPS MEDICAL ACQUISITION CORPORATION By: /s/ WILLIAM E. CURRAN -------------------------------------------- Name: William E. Curran Title: President and Director PHILIPS HOLDING USA INC. By: /s/ WILLIAM E. CURRAN -------------------------------------------- Name: William E. Curran Title: Chairman, President and Director KONINKLIJKE PHILIPS ELECTRONICS N.V. By: /s/ COR BOONSTRA -------------------------------------------- Name: Cor Boonstra Title: President, Chairman of the Board of Management and the Group Management Committee By: /s/ JAN H.M. HOMMEN -------------------------------------------- Name: Jan H.M. Hommen Title: Executive Vice-President, Chief Financial Officer, Member of the Board of Management and the Group Management Committee Date: November 17, 2000 3 4 EXHIBIT INDEX EXHIBIT NUMBER EXHIBIT DESCRIPTION - ------------ ------------------- 99(a)(8)(+) Complaint in Sidney Olmsted v. ADAC Laboratories, et al., No. CV793923, Superior Court of the State of California, County of Santa Clara. 99(a)(9)(+) Complaint in Gerber v. ADAC Laboratories, et al., No. CV793924, Superior Court of the State of California, County of Santa Clara. 99(a)(10)(+) Complaint in Boris Rimensberger v. ADAC Laboratories, et al. No. CV793928, Superior Court of the State of California, County of Santa Clara. (+) Filed as Exhibits 8, 9 and 10 to ADAC Laboratories' Amendment No. 2 to its Schedule 14D-9. -----END PRIVACY-ENHANCED MESSAGE-----